19/49) to 11% (14/128)
as CO2 replaced air for foam preparation
(P < .001).

Gillet,
2009205

1025 patients

UGFS for GSV or
SSV reﬂux

None

30-day saphenous occlusion: 90.3%. Side
effects: n ¼ 27 (2.6%), migraine (